Shannon Thyme Klinger - Feb 28, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Legal Officer
Signature
/s/ James Dillon, as Attorny-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 28, 2025
Transactions value $
-$8,488
Form type
4
Date filed
3/3/2025, 04:46 PM
Previous filing
Feb 28, 2025
Next filing
Mar 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +233 +0.94% 25K Feb 28, 2025 Direct F1
transaction MRNA Common Stock Tax liability -$3.51K -113 -0.45% $31.09 24.9K Feb 28, 2025 Direct F2
transaction MRNA Common Stock Options Exercise +329 +1.32% 25.2K Feb 28, 2025 Direct F1
transaction MRNA Common Stock Tax liability -$4.97K -160 -0.64% $31.09 25K Feb 28, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -233 -20.02% $0.00 931 Feb 28, 2025 Common Stock 233 Direct F1, F3
transaction MRNA Restricted Stock Units Options Exercise $0 -329 -11.12% $0.00 2.63K Feb 28, 2025 Common Stock 329 Direct F1, F4
transaction MRNA Stock Option (Right to Buy) Award $0 +55.5K $0.00 55.5K Mar 1, 2025 Common Stock 55.5K $30.96 Direct F5
transaction MRNA Restricted Stock Units Award $0 +34.7K $0.00 34.7K Mar 1, 2025 Common Stock 34.7K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.